June 2019 - Volume 3 - Issue - Contributor Index

Author:
S, C.
Author:
S.,
Author:
Saad, A.
Author:
Saad, S.
Author:
Saadeh, S.
Author:
Saavedra, D.

FLOW CYTOMETRY CHALLENGE FOR MEASURABLE RESIDUAL DISEASE MONITORING IN B-ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) PATIENTS RECEIVING TARGETED IMMUNOTHERAPY: PB1660

Bermejo, Yeguas A.; García-Sancho, Martín A.; Morón, Puig N.; More

HemaSphere. 3:768, June 2019.

Author:
Saavedra, S.
Author:
Sabatelli, S.

CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP): PF644

Mele, A.; Prete, E.; De Risi, C.; More

HemaSphere. 3:275-276, June 2019.

Author:
Sabattini, E.

“3C-UP” A NEW ADULT PHILADELPHIA NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUBGROUP: NOVEL MOLECULAR MARKERS: PS928

Ferrari, A.; Vitali, S.; Robustelli, V.; More

HemaSphere. 3:418, June 2019.

Author:
Saberi, M.
Author:
Sabir, M.
Author:
Sabirou, F.
Author:
Sabljic, N.
Author:
Sabol, I.

LOWER SERUM LEVELS OF ZINC AND MAGNESIUM ARE ASSOCIATED WITH WORSE ORAL CGVHD AND DYSGEUSIA IN CGVHD PATIENTS: PF773

Mravak-Stipetic, M.; Radman, M.; Desnica, L.; More

HemaSphere. 3:341, June 2019.

Author:
Sabri, A.
Author:
Sacchi, M.

NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA: 2-YEAR EXTENDED FOLLOW-UP FROM COHORT D OF THE PHASE 2 CHECKMATE 205 STUDY: S821

Domingo-Domènech, E.; Ramchandren, R.; Rueda, A.; More

HemaSphere. 3:363, June 2019.

NIVOLUMAB AND BRENTUXIMAB VEDOTIN-BASED, RESPONSE-ADAPTED TREATMENT IN PRIMARY REFRACTORY AND IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN CHECKMATE 744: S822

Leblanc, T.; Harker-Murray, P.; Mauz-Körholz, C.; More

HemaSphere. 3:363-364, June 2019.

Author:
Sacedón, R.
Author:
Sacha, T.

ENESTOP 192-WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT-FREE REMISSION (TFR) FOLLOWING SECOND-LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): PF411

Mahon, F.-X.; Boquimpani, C.; Takahashi, N.; More

HemaSphere. 3:158, June 2019.

CURRENT DOSE RECOMMENDATIONS FOR PONATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS CAN DIMINISH ADVERSE EVENTS WHILE MAINTAINING EFFICACY: PS1186

Garcia-Gutierrez, V.; Hernandez-Boluda, J. C.; Moiraghi, B.; More

HemaSphere. 3:540-541, June 2019.

Author:
Sachanas, S.

CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): CLINICAL SIGNIFICANCE OF ABSOLUTE CLONAL B CELL COUNTS: PS1258

Kalpadakis, C.; Pangalis, G.; Konstantinou, I.; More

HemaSphere. 3:575, June 2019.

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WITH INCREASED SERUM VON WILLEBRAND LEVELS AT DIAGNOSIS HAVE A SHORTER TIME TO TREATMENT: PB1895

Tryfou, ?.; Papaioannou, P.; Repousis, P.; More

HemaSphere. 3:863-864, June 2019.

BORTEZOMIB-HIGH DOSE METHYLPREDNISOLONE OFFERS IMPROVED HAEMATOLOGICAL RESPONSES AND OVERALL SURVIVAL COMPARED TO BORTEZOMIB-DEXAMETHASONE IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS: PB2127

Mahmood, A. S.; Sachchithanantham, S.; Harrison, S.; More

HemaSphere. 3:958, June 2019.

Author:
Sacher, J.
Author:
Sachs, C.
Author:
Sadeghi, F.
Author:
Sadelain, M.

A PHASE I FIRST-IN-HUMAN CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION: S1634

Palomba, M. L.; Batlevi, C.; Riviere, I.; More

HemaSphere. 3:755, June 2019.

Author:
Sadiku, S.
Author:
Saes, J.
Author:
Saevels, K.
Author:
Saeys, Y.
Author:
Saez, M. N.
Author:
Safavi, S.
Author:
Sag, E.
Author:
Sagawa, M.
Author:
saglio, G.

DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT-FREE REMISSION (TFR) IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AFTER STOPPING FRONTLINE (1L) NILOTINIB: ENESTFREEDOM 192-WK RESULTS: PF409

Ross, D. M.; Masszi, T.; Casares, Gómez M.T.; More

HemaSphere. 3:157, June 2019.

Author:
Sagou, K.
Author:
Sagüés, M.
Author:
Sagyndikov, G.
Author:
Sahin, D.
Author:
Sahin, F.

CLINICAL FEATURES AND TREATMENT OUTCOMES OF CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS IN TURKEY: REAL-WORLD DATA: PB1933

Saydam, G.; Ünal, A.; Kurtoglu, E.; More

HemaSphere. 3:879, June 2019.

Author:
Sahnane, N.

MYD88L265P MUTATION IN WM AND IGM-MGUS: COMPARISON OF FEASIBILITY AND BENEFIT BETWEEN DDPCR AND STANDARD ASQPCR IN CD19+ SELECTED AND UNSELECTED SAMPLES: PS1319

Drandi, D.; Furlan, D.; Ferrante, M.; More

HemaSphere. 3:602, June 2019.

Author:
Sahoo, S.
Author:
Said, D.
Author:
Saiki, R.

NGS-BASED COPY-NUMBER ANALYSIS IN MORE THAN 2,000 PATIENTS WITH MYELOID NEOPLASMS: S135

Saiki, R.; Shiozawa, Y.; Yoshizato, T.; More

HemaSphere. 3:19-20, June 2019.

Author:
Sail, K.

FACTORS IMPACTING TREATMENT SELECTION IN TREATMENT-NAÏVE PATIENTS WITH CLL: A MULTICENTER STUDY: PF381

Rhodes, J.; Sail, K.; Yazdy, Sarraf M.; More

HemaSphere. 3:142, June 2019.

Author:
Saillard, C.
Author:
Saini, L.

SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: PF587

Chen, C.; Gasparetto, C.; White, D.; More

HemaSphere. 3:245, June 2019.

A PHASE 1B/2 STUDY OF SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (SKD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PS1414

Gasparetto, C.; Lentzsch, S.; Schiller, G.; More

HemaSphere. 3:650, June 2019.

SAFETY AND EFFICACY OF COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASONE (SDD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS: S1606

Gasparetto, C.; Lentzsch, S.; Schiller, G.; More

HemaSphere. 3:740, June 2019.

Author:
Sait, S.
Author:
Saito, A.

REDUCED-INTENSITY IMMUNOCHEMOTHERAPY WITHOUT VINCRISTINE IN ELDERLY PATIENTS OLDER THAN 80 YEARS OLD WITH DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTRE, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL: PF301

Yoshida, I.; Suehiro, Y.; Hirabayashi, Y.; More

HemaSphere. 3:102-103, June 2019.

Author:
Saito, K.
Author:
Saito, R.
Author:
Saitoh, T.
Author:
Sajid, Z.
Author:
Sajjad, A.
Author:
Sakai, H.

EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPY: PF184

Shigematsu, A.; Ota, S.; Kobayashi, R.; More

HemaSphere. 3:44, June 2019.

Author:
Sakai, K.
Author:
Sakamoto, J.

TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4: PF407

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3:155-156, June 2019.

TARGETING T-CELL RECEPTOR SIGNALING PATHWAY BY DASATINIB IN RELAPSED/REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: PS1308

Kiyoki, Y.; Sakata-Yanagimoto, M.; Nguyen, T. B.; More

HemaSphere. 3:597, June 2019.

Author:
Sakellari, I.

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IMPROVES SURVIVAL IN AML PATIENTS WITH HIGH FLT3-ITD ALLELIC RATIO: PB1750

Papalexandri, A.; Kika, F.; Varelas, C.; More

HemaSphere. 3:804-805, June 2019.

Author:
Sakellariou, K.

COMPARISON OF RITUXIMAB DOSE-ADJUSTED EPOCH (R-DA-EPOCH) WITH RITUXIMAB-CHOP (R-CHOP) CHEMOTHERAPY IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): PF297

Vassilakopoulos, T.; Mellios, Z.; Verigou, E.; More

HemaSphere. 3:100-101, June 2019.

Show: